Inactive Instrument

TOTL BRAI

Equities

TTB

AU0000032435

Total Brain Limited Enters into Data Licensing Deal with Alto Neuroscience

December 29, 2021 at 02:10 am

Total Brain Limited entered a perpetual, non-exclusive license with Alto Neuroscience Inc. for its iSpot-D (International Study to Predict Optimized Treatment for Depression) research data, effective immediately. Total Brain will receive a one-off license fee of USD 500K payable USD 100k by 15 January 2022 and USD 400k within 15 days of the data transfer date which is estimated to occur before March 31, 2022. The transaction is subject to conventional commercial termination provisions.

Latest news about TOTL BRAI

Transcript : Total Brain Limited - Shareholder/Analyst Call	09/03/23
Total Brain Limited Reports Earnings Results for the Half Year Ended December 31, 2022	28/02/23	CI
Total Brain to Delist on Australian Bourse on March 1	14/02/23	MT
Transcript : Total Brain Limited - Shareholder/Analyst Call	31/01/23
David Daglio Steps Down from Board of Directors of Total Brain Limited	05/12/22	CI
Total Brain Completes Business Asset Sale to SonderMind; Shares Up 5%	01/11/22	MT
SonderMind Inc. acquired Assets of Total Brain Limited.	31/10/22	CI
Transcript : Total Brain Limited - Shareholder/Analyst Call	30/10/22
Total Brain Limited Auditor Raises 'Going Concern' Doubt	29/09/22	CI
Total Brain Limited Reports Earnings Results for the Full Year Ended June 30, 2022	31/08/22	CI
Total Brain Agrees to Salell Business for $10 Million	05/08/22	MT
SonderMind Inc. entered into an agreement to acquire Assets of Total Brain Limited for $10 million.	04/08/22	CI
Total Brain Limited announced that it expects to receive AUD 0.0396 million in funding	01/06/22	CI
VeriSIM Life and Total Brain Announce Strategic Collaboration Agreement Applying AI to Develop New Drugs for Neurological Disorders	26/05/22	CI
Total Brain Limited Announces 5-Year Extension of AARP Contract	10/05/22	CI
Transcript : Total Brain Limited, Q3 2022 Earnings Call, May 04, 2022	04/05/22
Total Brain Limited announced that it expects to receive AUD 1.278485 million in funding	04/04/22	CI
Total Brain Limited Provides Varga Capital Loan Update	30/03/22	CI
Total Brain Limited Announces Repayment of F45 Loan	21/03/22	CI
Total Brain Limited Reports Earnings Results for the Half Year Ended December 31, 2021	28/02/22	CI
Transcript : Total Brain Limited, Q2 2022 Earnings Call, Feb 03, 2022	02/02/22
Kerna Health Signs Deal with Total Brain Limited to Integrate Total Brain Platform into Existing Behavioral Health Technologies	13/01/22	CI
Australian Shares Hit Nearly Four-Month High Despite Record COVID-19 Cases	29/12/21	MT
Total Brain Surges 18% Following Licensing Deal With Alto Neuroscience	29/12/21	MT
Total Brain Limited Enters into Data Licensing Deal with Alto Neuroscience	29/12/21	CI

Chart TOTL BRAI

Duration

Period

More charts

Company Profile

Total Brain Limited is an Australia-based company focused on developing and selling brain health products. It is engaged in the development and commercialization of brain health products, primarily delivered to a range of users through Total Brain platform. The Company's Total Brain platform is a neuroscience-based mental health and brain performance solution that starts with a self-monitoring and self-care app for individuals that drives robust team analytics for companies and ongoing monitoring for providers. The Company's Total Brain app allows individuals to self-monitor brain capacities, screen for mental health risks, and improve overall mental health and brain performance with self-care exercises to improve overall brain capacity and mental health. The Total Brain app functions include self-monitoring brain capacities and mental state; screen for risk of common mental conditions; personalized self-care recommendations for improved mental health, and in-the-moment stress relief.

Sector

More about the company